Also found in: Dictionary, Thesaurus, Wikipedia.
Related to etanercept: infliximab


a soluble tumor necrosis factor receptor that inactivates tumor necrosis factor, used in treatment of rheumatoid arthritis; administered subcutaneously.



Pharmacologic class: Immunomodulator

Therapeutic class: Antiarthritic

Pregnancy risk category B


Reacts with and deactivates free-floating tumor necrosis factor, responsible for inflammation


Powder for injection: 25 mg in multiple-use vial

Prefilled syringe (single-use): 50 mg/ml

Indications and dosages

Moderately to severely active rheumatoid arthritis; ankylosing spondylitis; psoriatric arthritis

Adults: 50 mg subcutaneously q week given as a single injection. Dosages above 50 mg/week are not recommended.

Chronic moderate to severe plaque psoriasis

Adults ages 18 and older: 50 mg subcutaneously twice weekly (given 3 or 4 days apart) for 3 months, followed by reduction to a maintenance dosage of 50 mg weekly

Polyarticular-course juvenile rheumatoid arthritis

Children ages 4 to 17: 0.8 mg/kg subcutaneously q week, to a maximum of 50 mg weekly


• Hypersensitivity to drug or its components

• Sepsis


Use cautiously in:

• immunosuppression, chronic infection, heart failure

• latex allergy (needle cover of diluent syringe contains latex)

• elderly patients

• pregnant or breastfeeding patients

• children younger than age 4.


• Inject subcutaneously into thigh, abdomen, or upper arm.

• For adult, use single-use, 50 mg/ml prefilled syringe.

• For child weighing 63 kg (138 lb) or more, use single-use, 50 mg/ml pre-filled syringe for weekly dose; for child weighing 31 to 62 kg (68 to 137 lb), administer total weekly dose from multipleuse vial as two injections on same day or 3 or 4 days apart; for child weighing less than 31 kg (68 lb), give as a single weekly injection using multipleuse vial.

• Rotate injection sites.

Adverse reactions

CNS: asthenia, headache, depression, dizziness, paresthesia, fatigue, demyelinating disorders (such as multiple sclerosis and myelitis), cerebral hemorrhage, seizures, cerebrovascular accident (CVA)

CV: hypotension, hypertension, chest pain, deep-vein thrombosis, thrombophlebitis, myocardial ischemia, myocardial infarction (MI), heart failure

EENT: ocular inflammation, pharyngitis, rhinitis, sinusitis

GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia, anorexia, cholecystitis, abdominal abscess, GI hemorrhage, intestinal perforation, pancreatitis

GU: pyelonephritis, membranous glomerulonephropathy

Hematologic: anemia, aplastic anemia, leukopenia, pancytopenia, thrombocytopenia

Metabolic: hypomagnesemia

Musculoskeletal: bursitis, polymyositis, joint pain

Respiratory: cough, congestion, dyspnea, bronchitis, pneumonia, pulmonary embolism, interstitial lung disease

Skin: flushing, cellulitis, pruritus, rash, cutaneous vasculitis, urticaria, alopecia, angioedema

Other: altered taste, weight gain, adenopathy, fever, irritation at injection site, peripheral edema, flulike symptoms, autoantibody formation, lupus-like syndrome, serious infections, malignancies


None significant

Patient monitoring

Watch for signs and symptoms of malignancies, pancytopenia and infection.

Monitor for evidence of GI bleeding, lupus-like syndrome, and serious hypersensitivity reactions. Stop therapy immediately if these occur.

• Monitor CBC and coagulation studies.

Check for signs and symptoms of cardiac compromise and cerebrovascular events.

• Monitor pulmonary function test results periodically to assess lung status.

• Assess patient's ability to self-administer drug.

• Check for irritation at injection site. As needed, apply cool compresses.

• Examine eyes for conjunctival dryness. As needed, apply artificial tears.

Patient teaching

Tell patient to withhold dose and contact prescriber if he develops signs or symptoms of infection or is exposed to anyone with chickenpox.

Tell patient to immediately report hypersensitivity reaction, neurologic or respiratory problems, sudden weight gain, chest pain, or easy bruising or bleeding.

• Teach patient or caregiver how to administer drug and handle and dispose of equipment.

• Caution patient not to get live-virus vaccines.

• Tell female to inform prescriber if she is pregnant or breastfeeding.

• Advise patient to expect redness, swelling, and pain at injection site. Assure him that these problems will diminish over time.

• As appropriate, review all other significant and life-threatening adverse reactions mentioned above.


/eta·ner·cept/ (e-tan´er-sept) a soluble tumor necrosis factor receptor that inactivates tumor necrosis factor, used in the treatment of rheumatoid arthritis.


A drug that blocks tumor necrosis factor receptors and is used to treat autoimmune diseases, especially rheumatoid arthritis and psoriasis.


a biological agent.
indication It is used to treat acute, chronic rheumatoid arthritis that has not responded to other treatments.
contraindications Known hypersensitivity and sepsis prohibit its use.
adverse effects Adverse effects include abdominal pain, dyspepsia, headache, asthenia, dizziness, injection site reaction, cough, upper respiratory infection, non-upper respiratory infection, and sinusitis. Common side effects include rash, pharyngitis, and rhinitis.


Molecular medicine A genetically engineered molecule that blocks TNF activity, used to manage therapeutically refractive rheumatoid arthritis. See Rheumatoid arthritis.


A fusion protein for the human tumour necrosis factor (TNF) receptor produced by recombinant DNA technology and engineered to block the action of TNA. It is used to treat RHEUMATOID ARTHRITIS. The drug has been claimed to relieve depression and fatigue in PSORIASIS. A brand name is Enbrel.


cytokine inhibitor used to treat severe and/or non-responsive rheumatoid disease, active and progressive psoriatic arthropathy and severe ankylosing spondylitis
References in periodicals archive ?
Griffiths and his associates studied the efficacy and safety of GP2015 compared with etanercept, a tumor necrosis factor blocker, in the 2-year EGALITY trial.
His AS had been under control with etanercept for 43 months.
The study's innovative approach called for participating patients to switch treatments between the biosimilar etanercept and the originator product, Enbrei, three times during the course of the 52-week, randomized, double-blind trial.
Evaluating the effectiveness of etanercept was our main aim in this study.
All patients were receiving etanercept, adalimumab, or infliximab.
Etanercept is a tumor necrosis factor (TNF) inhibitor that has been shown to be effective and safe in the treatment of AS.
Cohen said, when 111 patients who were on methotrexate plus etanercept in year 1 stopped methotrexate (Arthritis Rheum.
It found that patients who had with low measures of disability at study entry, younger age at the onset of JIA, and fewer disease-modifying antirheumatic, drugs used before initiating etanercept achieved an excellent response to the treatment.
When the anti-TNF agents were analyzed individually, only etanercept was significantly associated with reduced risk.
The high level of efficacy of ustekinumab treatment that we observed was achieved with only two injections during the 12-week period, as compared with twice-weekly injections of etanercept, which may be important for improved treatment compliance.
In the etanercept group, major defects were seen in 9.